glucuronic acid has been researched along with Cancer of Ovary in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, L; Di, W; Liu, T; Qiu, L; Wang, X; Wang, Y; Zhou, J | 1 |
| Shea, LD; Shikanov, A; Woodruff, TK | 1 |
| Baghbani, F; Moztarzadeh, F | 1 |
| Dahut, WL; Figg, WD; Lakhani, NJ; Sparreboom, A; Veenstra, TD; Venitz, J; Xu, X | 1 |
| Aiello, C; Bignardi, G; Cafaggi, S; Caviglioli, G; De Totero, D; Leardi, R; Parodi, B; Russo, E; Stefani, R; Viale, M | 1 |
1 review(s) available for glucuronic acid and Cancer of Ovary
| Article | Year |
|---|---|
Bioengineering the ovarian follicle microenvironment.
Topics: Aging; Alginates; Animals; Cell Culture Techniques; Cryopreservation; Female; Fertility Preservation; Glucuronic Acid; Hexuronic Acids; Humans; Hydrogel, Polyethylene Glycol Dimethacrylate; Infertility, Female; Obesity; Oocytes; Ovarian Follicle; Ovarian Neoplasms; Ovary; Polycystic Ovary Syndrome; Reproductive Medicine; Stem Cells; Systems Biology; Tissue Engineering | 2014 |
1 trial(s) available for glucuronic acid and Cancer of Ovary
| Article | Year |
|---|---|
Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent, 2-methoxyestradiol.
Topics: 2-Methoxyestradiol; Administration, Oral; Antineoplastic Agents; Biotransformation; Chromatography, High Pressure Liquid; Drugs, Investigational; Estradiol; Female; Glucuronic Acid; Humans; In Vitro Techniques; Male; Microsomes, Liver; Molecular Structure; Ovarian Neoplasms; Oxidation-Reduction; Prostatic Neoplasms; Tandem Mass Spectrometry | 2007 |
3 other study(ies) available for glucuronic acid and Cancer of Ovary
| Article | Year |
|---|---|
Cisplatin-alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells.
Topics: Alginates; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Delayed-Action Preparations; Drug Delivery Systems; Endocytosis; Epidermal Growth Factor; ErbB Receptors; Female; Glucuronic Acid; Hexuronic Acids; Humans; Kinetics; Liposomes; Mice; Mice, Nude; Nanoparticles; Ovarian Neoplasms; Polyethylene Glycols; Rhodamines; Spheroids, Cellular | 2014 |
Bypassing multidrug resistant ovarian cancer using ultrasound responsive doxorubicin/curcumin co-deliver alginate nanodroplets.
Topics: Alginates; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Curcumin; Doxorubicin; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Glucuronic Acid; Hexuronic Acids; Humans; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms, Experimental; Ovarian Neoplasms; Particle Size; Surface Properties; Ultrasonics | 2017 |
Preparation and evaluation of nanoparticles made of chitosan or N-trimethyl chitosan and a cisplatin-alginate complex.
Topics: Alginates; Animals; Antineoplastic Agents; Apoptosis; Buffers; Cell Line, Tumor; Chitosan; Cisplatin; Dose-Response Relationship, Drug; Female; Glucuronic Acid; Hexuronic Acids; Humans; Hydrogen-Ion Concentration; Leukemia; Lung Neoplasms; Mice; Nanoparticles; Ovarian Neoplasms; Particle Size; Static Electricity | 2007 |